ArticleInternational journal of microbiology2012
Microbial translocation in chronic liver diseases.
Article in International journal of microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Pooled it
- Hepatic Encephalopathy in Cirrhotic Patients and Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis.BioMed research international · 2022Pooled it
- Human supplementation with Pediococcus acidilactici GR-1 decreases heavy metals levels through modifying the gut microbiota and metabolome.NPJ biofilms and microbiomes · 2022Trial
- Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study.Frontiers in cellular and infection microbiology · 2022Trial
- Liver Disease in Common Variable Immunodeficiency: Current Evidence and Knowledge Gaps.International journal of molecular sciences · 2026Review
- Spatially divergent metabolic impact of experimental toxoplasmosis: immunological and microbial correlates.mSystems · 2025Article
- Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.AIMS microbiology · 2025Review
- A new perspective on non-invasive diagnosis of non- alcoholic fatty liver disease: evidence integration of inflammatory and metabolic biomarkers based on a scoping review.Frontiers in endocrinology · 2025Article
- Case Report: Campylobacter Bacteremia in India.The American journal of tropical medicine and hygiene · 2024Article
- Management of liver disease and portal hypertension in common variable immunodeficiency (CVID).JHEP reports : innovation in hepatology · 2023Review
- Causal Associations between Gut Microbiota and Different Types of Dyslipidemia: A Two-Sample Mendelian Randomization Study.Nutrients · 2023Article
- Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation.Scientific reports · 2022Article
- Morphology of blood microbiota in healthy individuals assessed by light and electron microscopy.Frontiers in cellular and infection microbiology · 2022Article
- Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis.Frontiers in medicine · 2022Review
- Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota.Frontiers in medicine · 2022Review
- Article
- Dietary Nutrition and Gut Microbiota Composition in Patients With Hypertensive Disorders of Pregnancy.Frontiers in nutrition · 2022Article
- The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure.International journal of molecular sciences · 2021Review
- Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.Gut and liver · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal microflora is not only involved in the digestion of nutrients, but also in local immunity, forming a barrier against pathogenic microorganisms. The derangement of the gut microflora may lead to microbial translocation, defined as the passage of viable microorganisms or bacterial products (i.e., LPS, lipopeptides) from the intestinal lumen to the mesenteric lymph nodes and other extraintestinal sites. The most recent evidence suggests that microbial translocation (MT) may occur not only in cirrhosis, but also in the early stage of several liver diseases, including alcoholic hepatopathy and nonalcoholic fatty liver disease. Different mechanisms, such as small intestinal bacterial overgrowth, increased permeability of intestinal mucosa, and impaired immunity, may favor MT. Furthermore, MT has been implicated in the pathogenesis of the complications of cirrhosis, which are a significant cause of morbidity and mortality in cirrhotic subjects. Therapeutic strategies aiming at modulating the gut microflora and reducing MT have focused on antibiotic-based options, such as selective intestinal decontamination, and nonantibiotic-based options, such as prokinetics and probiotics. In particular, probiotics may represent an attractive strategy, even though the promising results of experimental models and limited clinical studies need to be confirmed in larger randomized trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.